Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Tirucherai (Princeton, United States of America), D. Yu (Silverado, United States of America), R. Revankar (Princeton, United States of America), G. Klinger (Princeton, United States of America), J. Van Lier (Groningen, Netherlands), J. Taubel (London, United Kingdom), T. Correll (Princeton, United States of America). BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study. 1398

Member's Comments

No comment yet.

Related content which might interest you: Effect of rifampin, a potent organic-anion-transporting polypeptide inhibitor (OATPi), on the PK of BMS-986278, a lysophosphatidic acid receptor (LPA1) antagonist Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020 Eosinophils from healthy children (1-3 years) and adults express high levels of prostaglandin D2 receptor 2 (DP2) Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics Year: 2018 Ethanol (EtOH) causes bronchoconstriction and plasma protein extravasation (PPE) in rodent airways via vanilloid receptor 1 (VR1) activation Source: Eur Respir J 2002; 20: Suppl. 38, 485s Year: 2002 Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Interaction of retinoid acid receptor-related orphan receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma Source: Annual Congress 2012 - Asthma and the genes: from GWAS to next generation transcriptome analyses Year: 2012 Protease-activated receptor 2 (PAR2) stimulation potentiates citric acid induced cough by sensitising the vanilloid receptor-1 (TRPV1) Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 The effect of leukotrienes and their receptor antagonists on calcium signalling in the cough receptors transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) Source: Annual Congress 2010 - Models of airways disease Year: 2010 Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020 Year: 2021 A new ultra-potent vanilloid receptor 1 (VR1) antagonist abates capsaicin and citric acid induced cough Source: Eur Respir J 2002; 20: Suppl. 38, 190s Year: 2002 Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils Source: Eur Respir J 2003; 22: Suppl. 45, 316s Year: 2003 Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017 A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 Source: Eur Respir J, 58 (4) 2100673; 10.1183/13993003.00673-2021 Year: 2021 Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Outcomes of a phase II study of ACT-293987, an oral IP receptor agonist, in pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Ethanol (EtOH) enhances the transient receptor potential vanilloid 1 (TRPV1) dependent cough in the guinea pig Source: Eur Respir J 2004; 24: Suppl. 48, 94s Year: 2004 Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001